Our partner SABINSA® came up with an innovative new product in the field of nutraceuticals. The novelty, called C3Reduct®, contains no less than 95% of Tetrahydrocurcuminoids (hereinafter referred to as THC) and has been nominated as a Novel Food by the EFSA statute.
C3Reduct® has countless pharmacological (antioxidant, anti-inflammatory, antimicrobial, anti-diabetic, anti-cancer, anti-allergic, hepatoprotective, cardioprotective, neuroprotective and nephroprotective) beneficial effects. It also outperformed the parent curcuminoids in some of these activities.
Curcumin C3 Reduct® is more easily absorbed through the gastrointestinal tract than curcumin, as the absence of a conjugated double bond in the hydrocarbon chain allows THC to bind more effectively to phospholipase A2 than regular curcumin.
A big advantage of C3Reduct® is its reduced yellow color (the product is of pure snow-white tone and does not leave any yellow/orange traces on the production lines).
Healing and soothing effects on digestion have been proven with long-term (23 weeks) use of curcumin C3 Reduct®. A significant reduction in colon polyps was found without any side effects in mice with azoxymethane (AOM) induced colon cancer.
Curcumin C3 Reduct® in a dose of 80 mg/kg of body weight for 45 days has shown a significant reduction of blood cholesterol level, antihyperlipidemic activity triglycerides, free fatty acids, phospholipids, very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol. It has also been shown to decrease serum high-density lipoprotein (HDL) after use.
In case of interest or questions, do not hesitate to contact us, our team will look forward to seeing you.
